Financing channel feed – Endpoints News

Financing channel feed

UK government plans to hike revenue clawback rates beginning in April

3 years ago

Tempus founders build a drug discovery startup, Pathos AI, with $40M in sight

3 years ago

Sangamo scraps public offering ‘after evaluating market conditions’

3 years ago

Dynacure to merge with Flamingo, rejoining two Ionis-affiliated biotechs

3 years ago

Tech, commerce-focused investor unveils $500M bet on healthcare

3 years ago

Cell therapy biotech from Stanford CAR-T leader Crystal Mackall nabs $200M for PhII

3 years ago

TandemAI raises $35M in Series A for small molecule discovery, wet labs

3 years ago

A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test

3 years ago

Regenerative cell biotech Thymmune launches with backing from George Church, John Maraganore

3 years ago

In push to expand its CAR-T therapies to US, China biotech Oricell raises additional $45M

3 years ago

Apellis jumps on the cash train after FDA approves its GA drug

3 years ago

Tangled in bankruptcy proceedings and legal tussle, Sorrento secures $75M to stay afloat

3 years ago

A small Connecticut biotech throws hat into IPO ring

3 years ago

Rare blood disorders biotech Hemab raises $135M, begins trek into clinic

3 years ago

Exclusive: Sanofi, Astellas venture arms add cash to Avilar's 'ATAC' mission

3 years ago

'Rare outliers': Feng Zhang eyes a new path to genetic medicine delivery with ex-Alnylam leaders and $193M

3 years ago

The top 100 biotech VCs: Who's staying at the table and what do they want now?

3 years ago

Working its way through a CRL on lead drug, Supernus taps $150M loan

3 years ago

Alexis Borisy, Zach Weinberg debut $520M idea for a new biotech investing model

3 years ago

Sesen Bio reaches deal with investor group, paving way for Carisma merger

3 years ago

A Texas-based biotech becomes the latest to enter the SPAC scene

3 years ago

PROTACs to RIPTACs: Arvinas founder snags $76M for next bet, Halda Therapeutics

3 years ago

Replay partners with MD Anderson’s Katy Rezvani, heads to clinic with new TCR NK cell company

3 years ago

Third time’s the charm: Cerevance’s Series B expands again

3 years ago

First page Previous page 37 38 394041 42 43 Next page Last page